The antagonistic interaction between adenosine and dopamine receptors could have
important pathophysiological and therapeutic implications in Parkinson's disease (PD). The …

KF17837 is a novel selective adenosine A 2A receptor antagonist. Oral administration of
KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses …

The adenosine A2A receptor has been implicated in the underlying biology of various
neurological and psychiatric disorders, including Parkinson's disease (PD) and depression …

[Frontiers in Bioscience 13, 2391-2399, January 1, 2008] 2391 Adenosine A1-A2A receptor
heteromers: new targets for caffeine in Page 1 [Frontiers in Bioscience 13, 2391-2399, January …

In rats with unilateral 6‐hydroxydopamine lesions of the dopaminergic nigrostriatal pathway,
administration of the A2a adenosine antagonist SCH 58261 alone did not induce any motor …

To determine the functions of striatal adenosine A2a receptors in vivo, the effects of a
selective agonist, 2‐[4‐(2‐carboxyethyl) phenethylamino]‐5′‐N …

A2A adenosine receptors are highly expressed in the striatum where they modulate
dopaminergic activity. The role of A2A receptors in psychostimulant action is less well …

Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease
(PD), and the central blockade of adenosine A1 receptor improves cognitive function. In the …

Adenosine A1 receptors in the brain are believed to play an important role in brain
functioning. We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1 …

Adenosine A 2A receptor antagonism is a new therapeutic strategy in the symptomatic
treatment of Parkinson's disease (PD). This review addresses how adenosine A 2A …